source
- Roivant reports Lisraya beats placebo in Phase 3 trials for non-infectious uveitisRoivant and its spinout Priovant announced that Lisraya, an immune-modifying oral drug, showed statistically significant benefit over placebo in two Phase 3 trials for non-infectious uveitis. The…
- Experts suggest emphasizing measles survival rates to boost vaccine trustThe United States has reported more than 4,400 measles cases this year, roughly twice the number recorded in 2025. At the same time, vaccination rates have fallen in over 1,600 counties between 201…